Patent Update: Angiotensin-II Antagonists: Patent Activity since the Discovery of DuP-753

[1]  D. Streeten,et al.  Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. , 1975, The New England journal of medicine.

[2]  R. Stevenson,et al.  Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors , 1988, British medical journal.

[3]  R. Re.  The renin-angiotensin systems. , 1987, The Medical clinics of North America.

[4]  M. Rawlins,et al.  Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. , 1987, British medical journal.

[5]  R. Skidgel,et al.  The broad substrate specificity of human angiotensin I converting enzyme. , 1987, Clinical and experimental hypertension. Part A, Theory and practice.

[6]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. , 1991, The Journal of pharmacology and experimental therapeutics.

[7]  N. Aiyar,et al.  Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  P. Timmermans,et al.  The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist , 1992, Medicinal research reviews.

[9]  R. Panek,et al.  Subclasses of angiotensin II binding sites and their functional significance. , 1990, Molecular pharmacology.

[10]  P. Timmermans,et al.  Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. , 1991, The Journal of pharmacology and experimental therapeutics.

[11]  U. Steckelings,et al.  Angiotensin II Receptor Subtypes: Characterization, Signalling Mechanisms, and Possible Physiological Implications , 1993, Frontiers in Neuroendocrinology.

[12]  C. Dollery,et al.  Effect of enalapril on the skin response to bradykinin in man. , 1987, British journal of clinical pharmacology.

[13]  P. Halushka,et al.  1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. , 1991 .

[14]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[15]  E. G. Erdös,et al.  Purification and characterization of human converting enzyme (kininase II) , 1981, Peptides.

[16]  P. Timmermans,et al.  DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists. , 1991, Biochemical and biophysical research communications.

[17]  N. Lydon,et al.  The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. , 1992, Biochemical and biophysical research communications.

[18]  P. Timmermans,et al.  The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. , 1990, Journal of medicinal chemistry.

[19]  R. Chang,et al.  Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. , 1991, Journal of medicinal chemistry.

[20]  W. Greenlee,et al.  Chapter 7. Angiotensin / Renin Modulators , 1991 .

[21]  D. Burt,et al.  Molecular biology of the renin-angiotensin system. , 1988, The American journal of physiology.

[22]  J. Wood,et al.  Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? , 1992, Pharmacology & toxicology.

[23]  P. Timmermans,et al.  EXP 6803, A Nonpeptide Angiotensin II Receptor Antagonist , 1989 .

[24]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[25]  R. Heel,et al.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1986, Drugs.

[26]  S. Whitebread,et al.  Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. , 1991, Biochemical and biophysical research communications.

[27]  S. Whitebread,et al.  Preliminary biochemical characterization of two angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[28]  J. Major,et al.  New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives. , 1992, Journal of medicinal chemistry.